JP6845691B2 - 免疫療法のための調節粒子 - Google Patents

免疫療法のための調節粒子 Download PDF

Info

Publication number
JP6845691B2
JP6845691B2 JP2016527304A JP2016527304A JP6845691B2 JP 6845691 B2 JP6845691 B2 JP 6845691B2 JP 2016527304 A JP2016527304 A JP 2016527304A JP 2016527304 A JP2016527304 A JP 2016527304A JP 6845691 B2 JP6845691 B2 JP 6845691B2
Authority
JP
Japan
Prior art keywords
nanoparticle composition
cells
nanoparticles
polymer
delivery vehicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016527304A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536312A (ja
JP2016536312A5 (enExample
Inventor
タレク ファーミー，
タレク ファーミー，
ブライアン ホースバーグ，
ブライアン ホースバーグ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of JP2016536312A publication Critical patent/JP2016536312A/ja
Publication of JP2016536312A5 publication Critical patent/JP2016536312A5/ja
Priority to JP2020028423A priority Critical patent/JP6929572B2/ja
Application granted granted Critical
Publication of JP6845691B2 publication Critical patent/JP6845691B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2016527304A 2013-11-01 2014-10-31 免疫療法のための調節粒子 Active JP6845691B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020028423A JP6929572B2 (ja) 2013-11-01 2020-02-21 免疫療法のための調節粒子

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361899080P 2013-11-01 2013-11-01
US61/899,080 2013-11-01
US201462040242P 2014-08-21 2014-08-21
US62/040,242 2014-08-21
PCT/US2014/063545 WO2015066535A1 (en) 2013-11-01 2014-10-31 Modular particles for immunotherapy

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020028424A Division JP2020075940A (ja) 2013-11-01 2020-02-21 免疫療法のための調節粒子
JP2020028423A Division JP6929572B2 (ja) 2013-11-01 2020-02-21 免疫療法のための調節粒子

Publications (3)

Publication Number Publication Date
JP2016536312A JP2016536312A (ja) 2016-11-24
JP2016536312A5 JP2016536312A5 (enExample) 2017-10-19
JP6845691B2 true JP6845691B2 (ja) 2021-03-24

Family

ID=51999513

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016527304A Active JP6845691B2 (ja) 2013-11-01 2014-10-31 免疫療法のための調節粒子
JP2020028424A Withdrawn JP2020075940A (ja) 2013-11-01 2020-02-21 免疫療法のための調節粒子
JP2020028423A Active JP6929572B2 (ja) 2013-11-01 2020-02-21 免疫療法のための調節粒子
JP2022043714A Withdrawn JP2022078345A (ja) 2013-11-01 2022-03-18 免疫療法のための調節粒子

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020028424A Withdrawn JP2020075940A (ja) 2013-11-01 2020-02-21 免疫療法のための調節粒子
JP2020028423A Active JP6929572B2 (ja) 2013-11-01 2020-02-21 免疫療法のための調節粒子
JP2022043714A Withdrawn JP2022078345A (ja) 2013-11-01 2022-03-18 免疫療法のための調節粒子

Country Status (11)

Country Link
US (3) US9884026B2 (enExample)
EP (1) EP3062779B1 (enExample)
JP (4) JP6845691B2 (enExample)
KR (2) KR20190126452A (enExample)
CN (2) CN105848649B (enExample)
AU (4) AU2014342004B2 (enExample)
CA (2) CA2987519A1 (enExample)
ES (1) ES2982087T3 (enExample)
RU (1) RU2672055C2 (enExample)
WO (1) WO2015066535A1 (enExample)
ZA (1) ZA201602826B (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2347775T3 (da) 2005-12-13 2020-07-13 Harvard College Skabeloner til celletransplantation
CN107648668B (zh) 2010-10-06 2021-06-18 哈佛学院董事会 用于基于材料的细胞疗法的可注射的成孔水凝胶
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
EP3939572B1 (en) 2012-04-12 2024-03-27 Yale University Vehicles for controlled delivery of different pharmaceutical agents
CN104244929B (zh) 2012-04-16 2017-04-05 哈佛学院董事会 用于调节免疫反应的介孔二氧化硅组合物
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
EP3760223A1 (en) 2013-04-03 2021-01-06 N-Fold Llc Nanoparticle composition for desensitizing a subject to peanut allergens
CN105848649B (zh) 2013-11-01 2019-08-02 耶鲁大学 用于免疫疗法的模块化粒子
EP3094314B1 (en) * 2014-01-16 2021-06-23 MUSC Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents
US20170173005A1 (en) 2014-03-27 2017-06-22 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
EP3250250A4 (en) * 2015-01-30 2019-05-22 President and Fellows of Harvard College PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
ES2993458T3 (en) 2015-03-16 2024-12-30 Pdx Pharmaceuticals Inc Cross-linked polymer modified nanoparticles
JP7094533B2 (ja) 2015-04-10 2022-07-04 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫細胞捕捉デバイスおよびその製造および使用方法
CN107708674A (zh) 2015-05-22 2018-02-16 阿菲欧斯公司 联合hiv疗法
MX2017015127A (es) * 2015-05-27 2018-06-22 Univ Northwestern Particulas modificadas por carbohidratos y formulaciones en particulas para modular una respuesta inmunitaria.
CN107708672A (zh) * 2015-06-15 2018-02-16 华盛顿大学 用于延长血液和淋巴组织中的药物水平的多药脂质纳米颗粒组合物和相关方法
JP6882782B2 (ja) 2015-08-04 2021-06-02 デューク ユニバーシティ 遺伝子コードされた本質的に無秩序な送達用ステルスポリマーおよびその使用方法
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
EP3411475B1 (en) 2016-02-06 2025-08-27 President and Fellows of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
WO2017144543A1 (en) * 2016-02-22 2017-08-31 Onxeo Combination therapies comprising immuno-oncology agents and belinostat
EP3804620B1 (en) * 2016-03-01 2022-02-16 North Carolina State University Enhanced cancer immunotherapy by microneedle patch-assisted delivery
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
CA3029813A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
CN115537372A (zh) 2016-07-13 2022-12-30 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
EP3493842A4 (en) 2016-08-02 2020-07-29 President and Fellows of Harvard College BIOMATERIALS TO MODULATE IMMUNE RESPONSES
JP2020500150A (ja) 2016-09-23 2020-01-09 デューク ユニバーシティ 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
CA3056802A1 (en) * 2017-03-16 2018-09-20 Children's Medical Center Corporation Non-viral, non-cationic nanoparticles and uses thereof
CA3056797A1 (en) 2017-03-16 2018-09-20 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
KR20210032924A (ko) 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
WO2019147954A1 (en) 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
GB201804634D0 (en) * 2018-03-22 2018-05-09 Aqdot Ltd Emulsion stabiliser
EP3788343B1 (en) 2018-04-30 2024-03-27 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
US11517628B2 (en) * 2018-05-09 2022-12-06 Yale University Particles for spatiotemporal release of agents
US20210275588A1 (en) * 2018-07-10 2021-09-09 The Regents Of The University Of California Biomolecule Coated Particles and Films and Uses Thereof
KR20210044212A (ko) * 2018-07-12 2021-04-22 더 리젠츠 오브 더 유니버시티 오브 미시간 면역 반응을 조절할 수 있는 금속 함유 제형의 조성물 및 방법
WO2020028806A1 (en) 2018-08-02 2020-02-06 Duke University Dual agonist fusion proteins
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
CA3113645A1 (en) * 2018-09-20 2020-03-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Targeting moiety-drug grafted immune cell compositions and methods of use
WO2020072495A1 (en) 2018-10-01 2020-04-09 The Board Of Trustees Of The Leland Stanford Junior University Injectable hydrogels for controlled release of immunomodulatory compounds
CA3115677A1 (en) * 2018-10-19 2020-04-23 University Of Rochester Immune modulators in combination with radiation treatment for advanced pancreatic cancer
RU2706427C1 (ru) * 2018-12-27 2019-11-19 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" Способ лечения онкологических заболеваний с помощью инъекций лекарственного препарата
WO2020150623A1 (en) * 2019-01-18 2020-07-23 University Of Georgia Research Foundation, Inc. Salt nanoparticles and compositions and methods of use thereof
US12263252B2 (en) 2019-06-05 2025-04-01 The Florida International University Board Of Trustees Biotherapy for viral infections using biopolymer based micro/nanogels
US20200383932A1 (en) * 2019-06-05 2020-12-10 The Florida International University Board Of Trustees Biotherapy for viral infections using biopolymer based micro/nanogels
WO2021011496A1 (en) * 2019-07-12 2021-01-21 Oregon Health & Science University Immunotherapeutic constructs and methods of their use
CA3139714A1 (en) 2019-07-12 2021-01-21 Wassana Yantasee Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
US20220249389A1 (en) * 2019-07-12 2022-08-11 Oregon Health & Science University Immunotherapeutic constructs and methods of their use
US20220331415A1 (en) * 2019-09-18 2022-10-20 The Regents Of The University Of California Immunoactive microparticles and uses thereof
RU2712212C1 (ru) * 2019-10-28 2020-01-27 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" Способ лечения онкологических заболеваний с помощью инъекций лекарственного препарата
BR112022010952A2 (pt) * 2019-12-05 2022-09-06 West Virginia Univ Board Of Governors On Behalf Of West Virginia Univ Nanosferas de plga carregadas de proteína
WO2021137611A1 (ko) * 2019-12-30 2021-07-08 (주)테라베스트 나노 구조체가 부착된 면역세포
US20230093708A1 (en) * 2020-03-04 2023-03-23 Duke University Protein nanoparticle design and application
WO2021231942A1 (en) * 2020-05-15 2021-11-18 The Board Of Trustees Of The Leland Stanford Junior University Toll-like receptor (tlr) agonist nanoparticles and uses thereof
WO2022006011A1 (en) * 2020-07-01 2022-01-06 Cello Therapeutics, Inc. Platelet membrane coated nanoparticles and uses thereof
CN112451504B (zh) * 2020-11-09 2022-10-18 四川大学华西医院 一种载EBV-LMP2 mRNA的核-壳纳米粒的制备方法及应用
US11672875B2 (en) 2021-03-17 2023-06-13 Saint Louis University Nanoparticle-alginate gels for X-ray imaging of the vasculature
US20240180849A1 (en) * 2021-04-20 2024-06-06 Purdue Research Foundation Immunofunctional carrier, methods of uses, and composition matters as an antitumor immunotherapy
GB2605996B (en) * 2021-04-21 2024-09-25 Act Therapeutics Ltd Enhancement of treatment with immunotherapeutic agents
WO2022225203A1 (ko) * 2021-04-23 2022-10-27 서울대학교산학협력단 대식세포의 활성 조절용 조성물
WO2023113545A1 (ko) * 2021-12-16 2023-06-22 주식회사 포투가바이오 αPD-1를 포함하는 수지상 세포 모방 기능성 나노구조체 및 이의 제조방법
WO2023113550A1 (ko) * 2021-12-16 2023-06-22 주식회사 포투가바이오 수지상세포 모방 기능성 나노구조체 및 이의 제조방법
WO2024128868A1 (ko) * 2022-12-15 2024-06-20 주식회사 포투가바이오 αPD-1를 포함하는 수지상 세포 모방 기능성 나노구조체 및 이의 제조방법
CN117731637A (zh) * 2023-12-20 2024-03-22 上海爱莫思生物技术有限公司 一种mdp纳米颗粒及其应用
WO2025149619A1 (en) * 2024-01-12 2025-07-17 Topas Therapeutics Gmbh Nanoparticles comprising amphiphilic polymers and lipids for the targeted delivery of antigens
CN120324344B (zh) * 2025-04-18 2025-10-17 广州医科大学附属第一医院横琴医院(横琴粤澳深度合作区中心医院) 一种肿瘤微环境响应型级联靶向小激活核酸纳米药物的制备方法及其应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5210079A (en) 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
US5354867A (en) 1988-12-06 1994-10-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
WO1995015746A1 (en) 1993-12-10 1995-06-15 The School Of Pharmacy Liposome delivery systems
US7411051B2 (en) 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US7052694B2 (en) 2002-07-16 2006-05-30 Mayo Foundation For Medical Education And Research Dendritic cell potentiation
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US7785578B2 (en) 2002-10-11 2010-08-31 Aciont, Inc. Non-invasive ocular drug delivery
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US20060099203A1 (en) 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
EP1768692B8 (en) 2004-07-01 2015-06-17 Yale University Targeted and high density drug loaded polymeric materials
US20070166281A1 (en) 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
PL1899364T5 (pl) * 2005-05-17 2024-12-09 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
EP3130350A1 (en) 2005-06-08 2017-02-15 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
WO2007005754A2 (en) 2005-07-01 2007-01-11 Alza Corporation Liposomal delivery vehicle for hydrophobic drugs
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
US20070243184A1 (en) 2005-11-08 2007-10-18 Steven Fischkoff Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
US8658608B2 (en) 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
EP1966765A2 (en) 2005-12-20 2008-09-10 Philips Intellectual Property & Standards GmbH Method for movement compensation of image data
JP2008053276A (ja) 2006-08-22 2008-03-06 Nec Electronics Corp 半導体装置の製造方法
NZ720288A (en) 2006-12-27 2020-02-28 Harvard College Compositions and methods for the treatment of infections and tumors
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
AU2008240155B2 (en) * 2007-04-13 2012-09-20 University Of North Texas Health Science Center At Fort Worth Formulation of active agent loaded activated PLGA nanoparticles for targeted cancer nano-therapeutics
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
EP2177230A4 (en) 2007-08-09 2011-04-27 Daiichi Sankyo Co Ltd IMMUNOLIPOSOM AS INDUCTOR OF APOPTOSIS INTO DEATH DOMAIN-CONTAINING RECEPTOR EXPRESSING CELL
TW200938224A (en) 2007-11-30 2009-09-16 Medarex Inc Anti-B7H4 monoclonal antibody-drug conjugate and methods of use
EP2927240A1 (en) 2008-08-25 2015-10-07 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
WO2010059253A2 (en) * 2008-11-24 2010-05-27 Massachusets Institute Of Technology Methods and compositions for localized agent delivery
WO2010083337A2 (en) 2009-01-15 2010-07-22 The Regents Of The University Of Califorinia Composite nanostructures and methods for making and using them
CN102596178B (zh) 2009-10-26 2014-12-03 石药集团中奇制药技术（石家庄）有限公司 具有磺丁基醚环糊精盐内水相的脂质体
US20110262406A1 (en) 2010-04-21 2011-10-27 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
US20110293690A1 (en) 2010-05-27 2011-12-01 Tyco Healthcare Group Lp Biodegradable Polymer Encapsulated Microsphere Particulate Film and Method of Making Thereof
JP2013531043A (ja) 2010-07-16 2013-08-01 ザ・ジョンズ・ホプキンス・ユニバーシティー 癌の免疫療法のための方法及び組成物
CA2817250A1 (en) 2010-11-18 2012-05-24 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy
BR112013028570A2 (pt) * 2011-05-09 2019-09-24 Institut Quim De Sarria nanopartículas poliméricas para administração de fármacos
EP3939572B1 (en) 2012-04-12 2024-03-27 Yale University Vehicles for controlled delivery of different pharmaceutical agents
CN105848649B (zh) 2013-11-01 2019-08-02 耶鲁大学 用于免疫疗法的模块化粒子

Also Published As

Publication number Publication date
US10751291B2 (en) 2020-08-25
AU2019246802B2 (en) 2021-05-27
US9884026B2 (en) 2018-02-06
JP2020073617A (ja) 2020-05-14
CA2929277A1 (en) 2015-05-07
JP2022078345A (ja) 2022-05-24
CA2987519A1 (en) 2015-05-07
ZA201602826B (en) 2019-10-30
US20210015758A1 (en) 2021-01-21
CA2929277C (en) 2018-01-16
AU2019246802A1 (en) 2019-10-31
CN105848649B (zh) 2019-08-02
KR102460800B1 (ko) 2022-10-31
EP3062779B1 (en) 2024-06-12
AU2017272274A1 (en) 2018-01-04
US20180200196A1 (en) 2018-07-19
RU2672055C2 (ru) 2018-11-09
CN110302162A (zh) 2019-10-08
AU2021221886A1 (en) 2021-09-23
WO2015066535A1 (en) 2015-05-07
JP2016536312A (ja) 2016-11-24
BR112016009643A8 (pt) 2021-02-23
AU2014342004B2 (en) 2017-10-26
RU2016121422A (ru) 2017-12-04
US20160303052A1 (en) 2016-10-20
KR20160085794A (ko) 2016-07-18
ES2982087T3 (es) 2024-10-14
AU2014342004A1 (en) 2016-05-26
JP2020075940A (ja) 2020-05-21
JP6929572B2 (ja) 2021-09-01
EP3062779A1 (en) 2016-09-07
BR112016009643A2 (pt) 2017-12-05
KR20190126452A (ko) 2019-11-11
CN105848649A (zh) 2016-08-10
EP3062779C0 (en) 2024-06-12

Similar Documents

Publication Publication Date Title
JP6929572B2 (ja) 免疫療法のための調節粒子
JP6608996B2 (ja) 異なる医薬品の制御送達のためのビヒクル
Goldberg Improving cancer immunotherapy through nanotechnology
CN109069527B (zh) 纳米颗粒、控释剂型和用于递送免疫治疗剂的方法
He et al. Nanotechnology-based approaches to promote lymph node targeted delivery of cancer vaccines
Wang et al. Polydopamine as the antigen delivery nanocarrier for enhanced immune response in tumor immunotherapy
Mittelheisser et al. Leveraging immunotherapy with nanomedicine
Bridgeman et al. Synthetic Organic Materials for Targeting Immunotherapies to Lymph Nodes
BR112016009643B1 (pt) Composição nanoparticulada
Yadav et al. Specialized Drug Delivery Systems
HK40002256A (en) Nanoparticles, controlled-release dosage forms, and methods for delivering an immunotherapeutic agent
HK40002256B (en) Nanoparticles, controlled-release dosage forms, and methods for delivering an immunotherapeutic agent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200221

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200221

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20200304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200326

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200415

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200416

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200529

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200603

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201117

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20201221

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210209

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210226

R150 Certificate of patent or registration of utility model

Ref document number: 6845691

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S201 Request for registration of exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R314201

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250